蔡莺, 马瑞卿, 夏奥, 许洪斌, 庞少军. 深部热疗联合5-Fu及顺铂腹腔化疗辅助治疗腹膜假黏液瘤的安全性及初步有效性研究[J]. 中国肿瘤临床, 2021, 48(11): 553-558. DOI: 10.3969/j.issn.1000-8179.2021.11.096
引用本文: 蔡莺, 马瑞卿, 夏奥, 许洪斌, 庞少军. 深部热疗联合5-Fu及顺铂腹腔化疗辅助治疗腹膜假黏液瘤的安全性及初步有效性研究[J]. 中国肿瘤临床, 2021, 48(11): 553-558. DOI: 10.3969/j.issn.1000-8179.2021.11.096
shu
Ying Cai, Ruiqing Ma, Ao Xia, Hongbin Xu, Shaojun Pang. The safety and preliminary efficacy of deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy as adjuvant treatment of pseudomyxoma peritonei[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(11): 553-558. DOI: 10.3969/j.issn.1000-8179.2021.11.096
Citation: Ying Cai, Ruiqing Ma, Ao Xia, Hongbin Xu, Shaojun Pang. The safety and preliminary efficacy of deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy as adjuvant treatment of pseudomyxoma peritonei[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(11): 553-558. DOI: 10.3969/j.issn.1000-8179.2021.11.096
shu

深部热疗联合5-Fu及顺铂腹腔化疗辅助治疗腹膜假黏液瘤的安全性及初步有效性研究

The safety and preliminary efficacy of deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy as adjuvant treatment of pseudomyxoma peritonei

    摘要
  • 摘要:
      目的  研究深部热疗联合5-Fu及顺铂（DDP）腹腔化疗辅助治疗腹膜假黏液瘤（pseudomyxoma peritonei，PMP）的安全性和初步有效性。
      方法  回顾性分析2018年1月至2019年12月航天中心医院接受深部热疗联合腹腔化疗患者的临床资料及随访结果，分析血常规、肝肾功、Karnofsky评分及并发症发生情况，探究深部热疗联合腹腔化疗对PMP的安全性和初步有效性。
      结果  本研究共纳入58例PMP患者，治疗前后白细胞（WBC）（P=0.064）、血红蛋白（HGB）（P=0.47）、天冬氨酸转移酶（AST）（P=0.08）、肌酐（CREA）（P=0.68）无统计学差异。丙氨酸转移酶（ALT）（P=0.01）、中性粒细胞百分比（NE%）（P=0.001）、中性粒细胞绝对值（NE#）（P=0.004）、血尿素氮（BUN）（P<0.001）和Karnofsky评分（P=0.017）存在统计学差异，分析治疗前后平均值，中性粒细胞（NE%、NE#）和生存质量（Karnofsky评分）较治疗前改善，ALT、BUN较治疗前下降。不良反应发生率为24.1%（1级20.7%，2级3.4%），均在对症治疗后好转。生存分析结果显示，1年和2年生存率分别为100.0%和96.4%。
      结论  深部热疗联合5-Fu及DDP腹腔化疗治疗PMP不损害肝肾功能、无明显骨髓抑制，不降低患者生存质量，不良反应可控，安全性较好，初步生存结果显示有效。

     

    Abstract:
      Objective  To explore the safety and preliminary efficacy of deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy in the adjuvant treatment of pseudomyxoma peritonei (PMP).
      Methods  We performed a retrospective analysis for the clinical data and follow-up results of the patients who received the treatment of deep hyperthermia combined with intraperitoneal chemotherapy in Aerospace Center Hospital from January 2018 to December 2019. The blood routine examination, blood biochemical examination (hepatic and kidney function examination), Karnofsky score and complications of the patients were collected. Combined with the follow-up results, we evaluated the safety and preliminary efficacy of deep hyperthermia combined with intraperitoneal chemotherapy on PMP.
      Results  A total of 58 patients with PMP were included in this study. There was no significant difference in white blood cell (WBC) (P=0.064), hemoglobin (HGB) (P=0.47), aspartate aminotransferase (AST) (P=0.08) and creatinine(CREA) (P=0.68) before and after treatment. There were statistical differences in alanine aminotransferase (ALT) (P=0.01), percentage of neutrophils (NE%) (P=0.001), absolute value of neutrophils (NE#) (P=0.004), blood urea nitrogen (BUN) (P=0.000) and Karnofsky score (P=0.017) before and after treatment. Further analysis of the average changes showed that neutrophil level (NE%, NE#) and quality of life (Karnofsky score) were improved compared with those before treatment. ALT and BUN were lower than before treatment. The total incidence of adverse reactions was 24.1% (Grade 1: 20.7%, Grade 2: 3.4%). The 1-year and 2-year survival rates were 100% and 96.4%, respectively.
      Conclusions  Deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy is a safe and preliminary effective treatment for PMP, which does not damage the liver and kidney function, has no obvious bone marrow suppression, does not reduce the quality of life, and the adverse reactions are controllable.

     

    • HTML全文
    • 参考文献(36)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回